S&P 500   3,309.76 (-0.36%)
DOW   29,031.98 (-0.53%)
QQQ   223.75 (-0.05%)
AAPL   317.77 (+0.02%)
FB   220.21 (-0.50%)
MSFT   165.91 (+0.13%)
GOOGL   1,483.92 (-0.02%)
AMZN   1,879.70 (-0.41%)
CGC   24.79 (+2.78%)
NVDA   249.96 (-0.04%)
BABA   218.07 (-1.93%)
MU   59.69 (+0.88%)
GE   11.74 (+3.26%)
TSLA   572.00 (+0.43%)
AMD   50.96 (-0.91%)
T   38.66 (-0.97%)
ACB   2.09 (+2.45%)
F   9.02 (-1.53%)
NFLX   337.29 (+3.46%)
PRI   123.84 (-2.22%)
DIS   141.41 (-1.81%)
GILD   63.21 (-0.35%)
S&P 500   3,309.76 (-0.36%)
DOW   29,031.98 (-0.53%)
QQQ   223.75 (-0.05%)
AAPL   317.77 (+0.02%)
FB   220.21 (-0.50%)
MSFT   165.91 (+0.13%)
GOOGL   1,483.92 (-0.02%)
AMZN   1,879.70 (-0.41%)
CGC   24.79 (+2.78%)
NVDA   249.96 (-0.04%)
BABA   218.07 (-1.93%)
MU   59.69 (+0.88%)
GE   11.74 (+3.26%)
TSLA   572.00 (+0.43%)
AMD   50.96 (-0.91%)
T   38.66 (-0.97%)
ACB   2.09 (+2.45%)
F   9.02 (-1.53%)
NFLX   337.29 (+3.46%)
PRI   123.84 (-2.22%)
DIS   141.41 (-1.81%)
GILD   63.21 (-0.35%)
S&P 500   3,309.76 (-0.36%)
DOW   29,031.98 (-0.53%)
QQQ   223.75 (-0.05%)
AAPL   317.77 (+0.02%)
FB   220.21 (-0.50%)
MSFT   165.91 (+0.13%)
GOOGL   1,483.92 (-0.02%)
AMZN   1,879.70 (-0.41%)
CGC   24.79 (+2.78%)
NVDA   249.96 (-0.04%)
BABA   218.07 (-1.93%)
MU   59.69 (+0.88%)
GE   11.74 (+3.26%)
TSLA   572.00 (+0.43%)
AMD   50.96 (-0.91%)
T   38.66 (-0.97%)
ACB   2.09 (+2.45%)
F   9.02 (-1.53%)
NFLX   337.29 (+3.46%)
PRI   123.84 (-2.22%)
DIS   141.41 (-1.81%)
GILD   63.21 (-0.35%)
S&P 500   3,309.76 (-0.36%)
DOW   29,031.98 (-0.53%)
QQQ   223.75 (-0.05%)
AAPL   317.77 (+0.02%)
FB   220.21 (-0.50%)
MSFT   165.91 (+0.13%)
GOOGL   1,483.92 (-0.02%)
AMZN   1,879.70 (-0.41%)
CGC   24.79 (+2.78%)
NVDA   249.96 (-0.04%)
BABA   218.07 (-1.93%)
MU   59.69 (+0.88%)
GE   11.74 (+3.26%)
TSLA   572.00 (+0.43%)
AMD   50.96 (-0.91%)
T   38.66 (-0.97%)
ACB   2.09 (+2.45%)
F   9.02 (-1.53%)
NFLX   337.29 (+3.46%)
PRI   123.84 (-2.22%)
DIS   141.41 (-1.81%)
GILD   63.21 (-0.35%)
Log in
(Ad)
Official tax return reveals how one trader nabbed annual gains of 228%, 309% and 339%. His tax return was released online, exposing this simple trading technique used to pocket nearly half a million in profits.

NASDAQ:VRTX - Vertex Pharmaceuticals Stock Price, Forecast & News

$234.99
+0.38 (+0.16 %)
(As of 01/23/2020 11:37 AM ET)
Today's Range
$231.74
Now: $234.99
$235.28
50-Day Range
$217.62
MA: $223.96
$235.83
52-Week Range
$163.68
Now: $234.99
$237.47
Volume17,595 shs
Average Volume1.07 million shs
Market Capitalization$60.43 billion
P/E Ratio28.48
Dividend YieldN/A
Beta1.47
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VRTX
CUSIP92532F10
Phone617-341-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.05 billion
Cash Flow$3.17 per share
Book Value$17.35 per share

Profitability

Net Income$2.10 billion

Miscellaneous

Employees2,500
Market Cap$60.43 billion
Next Earnings Date1/30/2020 (Confirmed)
OptionableOptionable

Receive VRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

Located just 25 miles from Cleveland... is a supergreenhouse unlike anything we've ever seen. Listed at over 1.4 million sq ft, (the size of 9 full-sized Costco warehouses), this marijuana grow house is capable of producing over 341,000 pounds of weed/year! And very soon it will come online and could turn a tiny 60-cent pot company into the dominator in the white-hot weed market.

Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

How will Vertex Pharmaceuticals' stock buyback program work?

Vertex Pharmaceuticals announced that its board has initiated a share buyback program on Wednesday, July 31st 2019, which allows the company to buyback $500,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 1.2% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's leadership believes its shares are undervalued.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its earnings results on Wednesday, October, 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.87 by $0.36. The pharmaceutical company earned $949.83 million during the quarter, compared to analysts' expectations of $942.90 million. Vertex Pharmaceuticals had a return on equity of 20.33% and a net margin of 59.24%. The business's revenue was up 21.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.09 earnings per share. View Vertex Pharmaceuticals' Earnings History.

When is Vertex Pharmaceuticals' next earnings date?

Vertex Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, January 30th 2020. View Earnings Estimates for Vertex Pharmaceuticals.

How can I listen to Vertex Pharmaceuticals' earnings call?

Vertex Pharmaceuticals will be holding an earnings conference call on Thursday, January 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for VRTX?

25 analysts have issued twelve-month price objectives for Vertex Pharmaceuticals' stock. Their forecasts range from $183.00 to $284.00. On average, they expect Vertex Pharmaceuticals' stock price to reach $228.54 in the next year. This suggests that the stock has a possible downside of 2.7%. View Analyst Price Targets for Vertex Pharmaceuticals.

What is the consensus analysts' recommendation for Vertex Pharmaceuticals?

25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 6 hold ratings and 19 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vertex Pharmaceuticals.

What are Wall Street analysts saying about Vertex Pharmaceuticals stock?

Here are some recent quotes from research analysts about Vertex Pharmaceuticals stock:
  • 1. Maxim Group analysts commented, "Vertex reported 2Q19 with cystic fibrosis (CF) revenue of $940M, beating consensus of $886.2M, up 25% y/y and 10% sequentially. All three approved CF drugs beat consensus; Kalydeco $262M vs. $254.5M, Orkambi $316M vs. $284.2M, and Symdeko $362M vs. $340.8M. Topline flowed through to the bottom line with $1.26 beating consensus of $1.07. Vertex ended the period with $4B in cash." (8/2/2019)
  • 2. HC Wainwright analysts commented, "Our price target of $220/share, is based on an equally weighted composite of: (a) $216/share, as a 30x multiple of taxed and diluted FY26 GAAP EPS of $22.94 discounted back to and (b) an NPV of $224/share (discount rate 11.0%, terminal growth rate of 2.0%). Risks to our investment thesis and target price include: (1) the failure of in further combination clinical studies; (2) the failure of to achieve our peak sales revenue; and (3) product competition." (8/1/2019)
  • 3. Needham & Company LLC analysts commented, "Vertex reported $857M in 1Q19 WW Cystic Fibrosis sales, above our $842M and consensus $849M ests. Symdeko/ Symkevi is primary growth driver, as expected. Sales and OpEx guidance are unch. Non-GAAP EPS was $1.14, above our $1.04 and consensus $1.01 ests. Full data set from both triple drug CF Phase 3 programs expected in 2Q19 and mgmt reiterated plans to select best regimen for NDA and MAA submissions in 3Q19 and 4Q19, respectively. Vertex moving a new once- daily corrector (VX-121) into triple drug Phase 2 trial w/ VX-561/TEZ in hopes of even greater efficacy. VX-814 announced as first candidate for AAT . A Phase 1 trial is underway w/ more backup cmpds to move into clinic in 2019. NaV1.8 pain strategy update likely in 2H19. BUY. Vertex likely to hold strong competitive position in CF for several yrs." (5/1/2019)
  • 4. According to Zacks Investment Research, "A significant increase in the eligible patient population for its CF drugs is driving sales growth at Vertex. Vertex’s third CF medicine, Symdeko, in a very short time, became the primary driver of growth in CF revenues in 2018. Vertex’s CF pipeline is also accelerating rapidly.  However, Vertex has faced some challenges with respect to commercialization of Orkambi in ex-U.S. markets due to re-imbursement hurdles. Meanwhile, a switch in patient base to Symdeko from Orkambi is also hurting sales of the latter. Also, competitive pressure is rising in the CF market with many other companies developing triple combo CF medicines. Also, Vertex’s dependence on just the CF franchise for growth is a concern. Shares have underperformed the industry this year so far." (3/8/2019)

Has Vertex Pharmaceuticals been receiving favorable news coverage?

News headlines about VRTX stock have trended somewhat positive on Thursday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vertex Pharmaceuticals earned a news impact score of 1.6 on InfoTrie's scale. They also gave news stories about the pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Vertex Pharmaceuticals.

Who are some of Vertex Pharmaceuticals' key competitors?

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include Companhia de Saneamento Bsc DEDSP (SBS), NVIDIA (NVDA), BioMarin Pharmaceutical (BMRN), Alibaba Group (BABA), Incyte (INCY), Alphabet (GOOG), Gilead Sciences (GILD), Netflix (NFLX), Micron Technology (MU) and Mercadolibre (MELI).

Who are Vertex Pharmaceuticals' key executives?

Vertex Pharmaceuticals' management team includes the folowing people:
  • Mr. Jeffrey Marc Leiden, Chairman, CEO & Pres (Age 63)
  • Mr. Michael J. Parini, Exec. VP and Chief Legal & Admin. Officer (Age 44)
  • Mr. Amit K. Sachdev, Exec. VP & Chief Regulatory Officer (Age 51)
  • Mr. Stuart A. Arbuckle, Exec. VP & Chief Commercial Officer (Age 53)
  • Dr. Jeffrey A. Chodakewitz, Sr. Advisor (Age 63)

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.28%), Assenagon Asset Management S.A. (0.10%), Manning & Napier Group LLC (0.09%), Welch & Forbes LLC (0.07%), Rhenman & Partners Asset Management AB (0.06%) and Gateway Investment Advisers LLC (0.06%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, Thomas Graney and William D Young. View Institutional Ownership Trends for Vertex Pharmaceuticals.

Which major investors are selling Vertex Pharmaceuticals stock?

VRTX stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Commerzbank Aktiengesellschaft FI, Rhenman & Partners Asset Management AB, Manning & Napier Group LLC, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Cullinan Associates Inc., United Services Automobile Association and State of Alaska Department of Revenue. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, David Altshuler, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle and William D Young. View Insider Buying and Selling for Vertex Pharmaceuticals.

Which major investors are buying Vertex Pharmaceuticals stock?

VRTX stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Trinity Street Asset Management LLP, CHURCHILL MANAGEMENT Corp, Janney Montgomery Scott LLC, Abner Herrman & Brock LLC, Brasada Capital Management LP, Pennsylvania Trust Co and Nisa Investment Advisors LLC. View Insider Buying and Selling for Vertex Pharmaceuticals.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $234.99.

How big of a company is Vertex Pharmaceuticals?

Vertex Pharmaceuticals has a market capitalization of $60.43 billion and generates $3.05 billion in revenue each year. The pharmaceutical company earns $2.10 billion in net income (profit) each year or $2.83 on an earnings per share basis. Vertex Pharmaceuticals employs 2,500 workers across the globe.View Additional Information About Vertex Pharmaceuticals.

What is Vertex Pharmaceuticals' official website?

The official website for Vertex Pharmaceuticals is http://www.vrtx.com/.

How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected]


MarketBeat Community Rating for Vertex Pharmaceuticals (NASDAQ VRTX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,356 (Vote Outperform)
Underperform Votes:  751 (Vote Underperform)
Total Votes:  2,107
MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals and other stocks. Vote "Outperform" if you believe VRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel